RespireRx Pharmaceuticals Inc (RSPI)

[apneaous]

Frankly, i am amazed the Phase 2B study has not received more traction and notoriety. Obstructive sleep apnea is implicated in type II diabetes, afib, left ventricular dysfunction, high blood pressure and a host of other maladies. The intermittent hypoxia is suspected to be a signficantly contributing cause. Obstructive sleep apnea therefore crosses many medical specialities.
As an apnea suffer and like many CPAP intolerant, i can tell you a sleep apnea drug, if little side effects, ought to be a real game changer. I like many have tried without success CPAP and dental appliances.
I would have expected those receiving the placebo to have some improvement also, but those taking placebo actualy got worse. That's impressive, no placebo effect IMHO. Those taking 10mg had the greatest effect. Given the short half life, they ought to be able to tinker with a coating to even out the absorption by the body, and perhaps achieve even better results.
Drabinol is now a Class III drug, so its no longer under the Class II regime, but presumably there will be some FDA wrangling with the FDA under Trump. For example, in March of 2017, the new THC-containing drug, Syndros, was classified as a Class II, to the surprise of many.
It's positive that this is simply repurposing an already approved drug so safety studies should not be an issue.
No pun intended, but this drug of RespireRX might be a sleeper. $3M for the whole value of the company? I have loaded up.